Randomised clinical trials (RCTs) have recently been conducted in patients with resected early-stage colorectal cancer (CRC) to evaluate the effects of aspirin versus placebo on disease-free survival (DFS) and overall survival (OS), particularly among those with tumours harbouring mutations in phosphatidylinositol 3-kinase (PI3K) pathway genes (most notably in the PIK3CA gene) or PTGS-2 (COX-2; cyclooxygenase-2) overexpression (Table 1).1–3
Radically different